Clinical Trial Update: Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing T4032, unpreserved bimatoprost 0.01%, to Lumigan 0.01% in patients with ocular hypertension or glaucoma. The study has completed and ass…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma
• Ocular Hypertension

Drugs mentioned

• Lumigan 0.01% (bimatoprost 0.01%)
• T4032 (unpreserved bimatoprost 0.01%) (bimatoprost 0.01%)

Snippet

Sponsor: Laboratoires Thea | Conditions: Glaucoma, Ocular Hypertension | Phase 3 | Status: COMPLETED